Guest Editor(s)
-
- Prof. Minming Zhang
- 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Website | E-mail
Special Issue Introduction
The reform of modern medical imaging technologies, which started decades ago, has largely reshaped the way we observe and quantify brain degeneration. Brain imaging methods such as magnetic resonance imaging (MRI) and positron emission tomography (PET) have been widely used to track neurodegeneration during aging or disease conditions. They demonstrated immense value in either scientific research or clinical applications, including disease diagnosis, prognosis, subtyping, and stratification. Novel brain imaging methods are still being continuously developed. Even with reduced scan time, they can provide structural information in finer details or functional information regarding specific pathological processing such as inflammation and glymphatic dysfunction. Furthermore, artificial intelligence can detect subtle imaging patterns imperceptible to human eyes, provide quantitative imaging features, and promote precision diagnosis. Based on convenient imaging tools, now it is much easier to build a large-scale prodromal community cohort to track neurodegeneration from early to late disease stages, charting the full course of brain degeneration during disease development. These data could provide invaluable information for understanding disease pathologies and developing tools for early diagnosis.
This special issue is focused on promoting research progress in the field of neurodegeneration imaging. We welcome reviews or research papers regarding scientific discoveries on brain aging or neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, vascular-related degeneration, etc.) achieved using various brain imaging methods (MRI, PET, etc.). Either laboratorial or clinical studies are welcome.
Keywords
Neurodegeneration, magnetic resonance imaging, positron emission tomography, Alzheimer’s Disease, Parkinson’s Disease
Submission Deadline
31 Oct 2022